biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD
Revolution Medicines
Revolution Medicines clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 700 Saginaw Dr., Redwood City, California 94063, US
- Founded
- 2014
- Employees
- 1,050
- Programs
- 26
- Drugs
- 28
- Patents
- 36
Revolution Medicines projects
10 ClinicalTrials.gov programs sponsored by Revolution Medicines.
Revolution Medicines has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
RMC-4630
Revolution Medicines
Solid Tumors
1 trial -
RMC-5127
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
RMC-5552
Revolution Medicines
Glioblastoma
1 trial -
RMC-5552
Revolution Medicines
Solid Tumors
1 trial -
RMC-6291
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC)
2 trials -
RMC-6291-001
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)
1 trial -
RMC-6291-101
Revolution Medicines
Participants with Advanced KRASG12C-Mutated Solid Tumors
1 trial -
RMC-9805
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
RMC-LUNG-101A
Revolution Medicines
Lung Cancer
1 trial -
RMC-LUNG-101B
Revolution Medicines
Lung Cancer
1 trial
Frequently asked questions
How many clinical projects does Revolution Medicines have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.